Xianli Chen

Hongfei Huang1
Maoshi Li1
Jie Wang1
1Hongfei Huang
1Maoshi Li
1Jie Wang
Learn More
BACKGROUND Hepatitis B e Antigen (HBeAg)-negative chronic hepatitis B (CHB) patients have an active liver disease with a high risk of progression to decompensated cirrhosis and hepatocellular carcinoma. The management strategy for HBeAg-negative CHB patients treated with nucleos(t)ide analogues (NUCs) is a topic of concern. To observe the outcomes for this(More)
  • 1